Literature DB >> 18561044

[The prevalence of metabolic syndrome and related factors in patients with schizophrenia].

Cem Cerit1, Eylem Ozten, Mustafa Yildiz.   

Abstract

OBJECTIVE: The aim of this study was to examine the prevalence of metabolic syndrome (MS) and related factors in patients with schizophrenia at an outpatient clinic.
METHOD: All 108 patients with schizophrenia or schizoaffective disorder that presented to the outpatient clinic between 12 May and 12 June 2006 were included in the study. Of the 108 patients, 100 whose biochemical analyses were completed were assessed.
RESULTS: The prevalence of MS was 21%, 34%, and 41% according to ATP III, ATP III-A, and IDF criteria, respectively. Increased waist circumference and low HDL level were frequent among the patients. The prevalence of MS increased with age. Mean age, duration of illness and duration of treatment were higher and family history of obesity was common in the patients with MS. DISCUSSION: The prevalence of ATP III-defined MS in patients with schizophrenia was lower compared to that reported in other studies; however, the prevalence of MS was high based on ATP III-A and IDF criteria. Patients with schizophrenia are at increased risk for MS or related metabolic problems. In particular, when risk factors such as older age, female gender, long duration of illness and treatment, and family history of obesity exist, clinicians should examine the metabolic condition of the patient. Increased waist circumference and low HDL level are probably the best predictors of MS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18561044

Source DB:  PubMed          Journal:  Turk Psikiyatri Derg        ISSN: 1300-2163


  8 in total

1.  Relationship Between Metabolic Syndrome and Clinical Features, and Its Personal-Social Performance in Patients with Schizophrenia.

Authors:  Omer Saatcioglu; Murat Kalkan; Nurhan Fistikci; Sakire Erek; Kasim Candas Kilic
Journal:  Psychiatr Q       Date:  2016-06

2.  The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey.

Authors:  M K Yazici; A E Anil Yağcioğlu; A Ertuğrul; N Eni; S Karahan; E Karaağaoğlu; S L Tokgözoğlu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-06-03       Impact factor: 5.270

3.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

4.  Metabolic syndrome in people with schizophrenia: a review.

Authors:  Marc DE Hert; Vincent Schreurs; Davy Vancampfort; Ruud VAN Winkel
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

5.  The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review.

Authors:  Evangelos Papanastasiou
Journal:  Ther Adv Psychopharmacol       Date:  2013-02

6.  The prevalence and clinical correlates of metabolic syndrome and cardiometabolic alterations in 430 drug-naive patients in their first episode of schizophrenia.

Authors:  Xiaoe Lang; Qinqin Liu; Hanliu Fang; Yongjie Zhou; Mattew T Forster; Zezhi Li; Xiangyang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2021-09-29       Impact factor: 4.530

7.  Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients.

Authors:  Rakesh K Chadda; Prashanth Ramshankar; Koushik S Deb; Mamta Sood
Journal:  J Pharmacol Pharmacother       Date:  2013-07

Review 8.  Metabolic syndrome in schizophrenia.

Authors:  Nidhi Malhotra; Sandeep Grover; Subho Chakrabarti; Parmanand Kulhara
Journal:  Indian J Psychol Med       Date:  2013-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.